Last reviewed · How we verify
Intravenous Solution Ateplase
Intravenous Solution Ateplase is a Small molecule drug developed by Department of Medical Services Ministry of Public Health of Thailand. It is currently FDA-approved.
At a glance
| Generic name | Intravenous Solution Ateplase |
|---|---|
| Sponsor | Department of Medical Services Ministry of Public Health of Thailand |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Low-dose Versus Standard Dose Alteplase in Acute Ischemic Stroke , 4 Monthes Prospective Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Solution Ateplase CI brief — competitive landscape report
- Intravenous Solution Ateplase updates RSS · CI watch RSS
- Department of Medical Services Ministry of Public Health of Thailand portfolio CI
Frequently asked questions about Intravenous Solution Ateplase
What is Intravenous Solution Ateplase?
Intravenous Solution Ateplase is a Small molecule drug developed by Department of Medical Services Ministry of Public Health of Thailand.
Who makes Intravenous Solution Ateplase?
Intravenous Solution Ateplase is developed and marketed by Department of Medical Services Ministry of Public Health of Thailand (see full Department of Medical Services Ministry of Public Health of Thailand pipeline at /company/department-of-medical-services-ministry-of-public-health-of-thailand).
What development phase is Intravenous Solution Ateplase in?
Intravenous Solution Ateplase is FDA-approved (marketed).
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing